[1] |
Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer[J]. Nature, 2018,553:446-454.
|
[2] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71:209-249.
|
[3] |
赵青春, 张子禾, 陈军. 2017 ASCO Ⅳ期非小细胞肺癌指南解读[J]. 中国医学前沿杂志(电子版), 2017,9:20-27.
|
[4] |
Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship[J]. Mayo Clin Proc, 2008,83:584-594.
|
[5] |
杨林, 赵晓红, 杨云梅. 非小细胞肺癌治疗的新进展[J]. 中华危重症医学杂志(电子版), 2017,10:416-420.
|
[6] |
Yu T, Xia Q, Gong T, et al. Molecular mechanism of acquired drug resistance in the EGFR-TKI resistant cell line HCC827-TR[J]. Thorac Cancer, 2020,11:1129-1138.
|
[7] |
Tong X, Tanino R, Sun R, et al. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer[J]. Respir Res, 2019,20:270-281.
|
[8] |
Signorile A, Sgaramella G, Bellomo F, et al. Prohibitins: a critical role in mitochondrial functions and implication in diseases[J]. Cells, 2019,8:1-14.
|
[9] |
Koushyar S, Jiang WG, Dart DA. Unveiling the potential of prohibitin in cancer[J]. Cancer Lett, 2015,369:316-322.
|
[10] |
Wu B, Chang N, Xi H, et al. PHB2 promotes tumorigenesis via RACK1 in non-small cell lung cancer[J]. Theranostics, 2021,11:3150-3166.
|
[11] |
Wei Y, Chiang WC, Sumpter RJ, et al. Prohibitin 2 is an inner mitochondrial membrane mitophagy receptor[J]. Cell, 2017,168:224-238.
|
[12] |
唐心蔚, 高天敏, 张君国. 自噬在非小细胞肺癌EGFR-TKI耐药中作用的研究进展[J]. 中华肺部疾病杂志(电子版), 2021,14:250-252.
|
[13] |
Wu B, Xiong J, Zhou Y, et al. Luteolin enhances TRAIL sensitivity in non-small cell lung cancer cells through increasing DR5 expression and Drp1-mediated mitochondrial fission[J]. Arch Biochem Biophys, 2020,692:1-12.
|
[14] |
张婧,杨自更,韦红梅等.敲减抗增殖蛋白2促进非小细胞肺癌细胞系A549凋亡[J].基础医学与临床,2023,43:1522-1529.
|
[15] |
Passaro A, Janne PA, Mok T, et al. Overcoming therapy resistance in EGFR-mutant lung cancer[J]. Nat Cancer, 2021,2: 377-391.
|